Array Biopharma Inc Drug Patent Portfolio

Array Biopharma Inc owns 2 orange book drugs protected by 21 US patents Given below is the list of Array Biopharma Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9562016 Preparation of and formulation comprising a MEK inhibitor 18 Oct, 2033
Active
US9598376 Preparation of and formulation comprising a MEK inhibitor 18 Oct, 2033
Active
US9980944 Preparation of and formulation comprising a MEK inhibitor 18 Oct, 2033
Active
US9474754 Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor 05 Aug, 2033
Active
US10258622 Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate 21 Nov, 2032
Active
US9387208 Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate 21 Nov, 2032
Active
US9763941 Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate 21 Nov, 2032
Active
US9314464 Compounds and compositions as protein kinase inhibitors 04 Jul, 2031
Active
US8501758 Compounds and compositions as protein kinase inhibitors 04 Mar, 2031
Active
US10005761 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
Active
US9593099 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
Active
US9593100 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
Active
US9850229 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
Active
US9850230 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
Active
USRE49556 Compounds and compositions as protein kinase inhibitors 27 Feb, 2030
Active
US8541575 3,4-diarylpyrazoles as protein kinase inhibitors 26 Feb, 2030
Active
US8946250 3,4-diarylpyrazoles as protein kinase inhibitors 23 Jul, 2029
Active
US7777050 N3 alkylated benzimidazole derivatives as MEK inhibitors 13 Mar, 2025
Active
US8178693 N3 alkylated benzimidazole derivatives as MEK inhibitors 13 Mar, 2023 Expired
US8193229 Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors 13 Mar, 2023 Expired
US8513293 Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal 13 Mar, 2023 Expired


Given below is the list of recent legal activities going on the following drug patents of Array Biopharma Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 11 Jul, 2024 US9562016
Expire Patent 08 Jul, 2024 US8193229
Petition to Accept Late Payment of Maintenance Fee Payment Filed 24 Jun, 2024 US8178693
Resp. to req. for info. sent under 37 CFR 1.750 21 Jun, 2024 US9593100
Withdrawal of Application for PTE 21 Jun, 2024 US9314464
Resp. to req. for info. sent under 37 CFR 1.750 21 Jun, 2024 US9314464
Resp. to req. for info. sent under 37 CFR 1.750 21 Jun, 2024 US9314464
Resp. to req. for info. sent under 37 CFR 1.750 21 Jun, 2024 US9593099
Withdrawal of Application for PTE 21 Jun, 2024 US9314464
Resp. to req. for info. sent under 37 CFR 1.750 21 Jun, 2024 US9593100
Expire Patent 17 Jun, 2024 US8178693
Payment of Maintenance Fee, 8th Year, Large Entity 14 Mar, 2024 US9474754
transaction for FDA Determination of Regulatory Review Period 30 Jan, 2024 US8178693
Withdrawal of Application for PTE 25 Jan, 2024 US8178693
Mail-Petition Decision - Granted 23 Jan, 2024 US8501758


Array Biopharma Inc Drug Patents' Oppositions Filed in EPO

Array Biopharma Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 19, 2018, by Generics [Uk] Limited (Trading As Mylan). This opposition was filed on patent number EP15177189A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15177189A Apr, 2018 Generics [UK] Limited (trading as Mylan) Revoked


Array Biopharma Inc's Family Patents

Array Biopharma Inc drugs have patent protection in a total of 58 countries. It's US patent count contributes only to 15.8% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Array Biopharma Inc Drug List

Given below is the complete list of Array Biopharma Inc's drugs and the patents protecting them.


1. Braftovi

Braftovi is protected by 15 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9474754 Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor 05 Aug, 2033
(8 years from now)
Active
US10258622 Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate 21 Nov, 2032
(8 years from now)
Active
US9387208 Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate 21 Nov, 2032
(8 years from now)
Active
US9763941 Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate 21 Nov, 2032
(8 years from now)
Active
US9314464 Compounds and compositions as protein kinase inhibitors 04 Jul, 2031
(6 years from now)
Active
US8501758 Compounds and compositions as protein kinase inhibitors 04 Mar, 2031
(6 years from now)
Active
US10005761 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
(5 years from now)
Active
US8501758 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
(5 years from now)
Active
US9593099 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
(5 years from now)
Active
US9593100 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
(5 years from now)
Active
US9850229 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
(5 years from now)
Active
US9850230 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
(5 years from now)
Active
USRE49556 Compounds and compositions as protein kinase inhibitors 27 Feb, 2030
(5 years from now)
Active
US8541575 3,4-diarylpyrazoles as protein kinase inhibitors 26 Feb, 2030
(5 years from now)
Active
US8946250 3,4-diarylpyrazoles as protein kinase inhibitors 23 Jul, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Braftovi's drug page


2. Mektovi

Mektovi is protected by 11 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9562016 Preparation of and formulation comprising a MEK inhibitor 18 Oct, 2033
(9 years from now)
Active
US9598376 Preparation of and formulation comprising a MEK inhibitor 18 Oct, 2033
(9 years from now)
Active
US9980944 Preparation of and formulation comprising a MEK inhibitor 18 Oct, 2033
(9 years from now)
Active
US9314464 Compounds and compositions as protein kinase inhibitors 04 Jul, 2031
(6 years from now)
Active
US10005761 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
(5 years from now)
Active
US9593100 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
(5 years from now)
Active
US9850229 Compounds and compositions as protein kinase inhibitors 27 Aug, 2030
(5 years from now)
Active
US7777050 N3 alkylated benzimidazole derivatives as MEK inhibitors 13 Mar, 2025
(5 months from now)
Active
US8178693 N3 alkylated benzimidazole derivatives as MEK inhibitors 13 Mar, 2023
(1 year, 6 months ago)
Expired
US8193229 Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors 13 Mar, 2023
(1 year, 6 months ago)
Expired
US8513293 Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal 13 Mar, 2023
(1 year, 6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mektovi's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List